Baseline severity and early tacrolimus trough are associated with time to minimal manifestations in steroid-free tacrolimus monotherapy for AChR antibody-positive myasthenia gravis
Baseline severity and early tacrolimus trough are associated with time to minimal manifestations in steroid-free tacrolimus monotherapy for AChR antibody-positive myasthenia gravis. // Revue Neurologique. – URL: https://www.sciencedirect.com/science/article/pii/S0035378726006387?dgcid=rss_sd_all
Baseline severity and early tacrolimus trough are associated with time to minimal manifestations in steroid-free tacrolimus monotherapy for AChR antibody-positive myasthenia gravis. Revue Neurologique. https://www.sciencedirect.com/science/article/pii/S0035378726006387?dgcid=rss_sd_all
“Baseline severity and early tacrolimus trough are associated with time to minimal manifestations in steroid-free tacrolimus monotherapy for AChR antibody-positive myasthenia gravis.” Revue Neurologique.
@article{article5988,
title = {Baseline severity and early tacrolimus trough are associated with time to minimal manifestations in steroid-free tacrolimus monotherapy for AChR antibody-positive myasthenia gravis},
journal = {Revue Neurologique},
url = {https://www.sciencedirect.com/science/article/pii/S0035378726006387?dgcid=rss_sd_all}
}